Earlier this year the only huge, properly-developed trial of renal denervation– the after highly-promising catheter-based mostly technological innovation that was broadly expected to “cure” tough instances of resistant hypertension– failed spectacularly. Numerous hypertension authorities think that ultimately the approach will demonstrate to be beneficial, but soon after the failure of Simplicity HTN-3 it is clear that there’s a fantastic deal of analysis that wants to be performed to find out just how– or if– this novel technology must be utilized.
In the US this does not existing a dilemma. The FDA has not approved renal denervation so it can only be utilized in a investigation setting. But that is not the case in Europe, in which the gadget is offered due to reduce requirements for gadget approval.
Correct now Europe’s largest interventional cardiology meeting, Euro PCR, is underway in Paris. Surprisingly– or probably not– renal denervation is still currently being heavily promoted in Europe. Right here is the evidence: a series of tweets by @Jeddacath, an interventional cardiologist at the Brigham & Women’s Hospital in Boston, who is attending the meeting.
This prompted some intriguing feedback:
Walking Dead Girl (Photograph credit: micadew)
The Walking Dead: Renal Denervation In Europe Just Can"t Be Stopped
Hiç yorum yok:
Yorum Gönder